» Articles » PMID: 33998154

MicroRNA-based Diagnostic and Therapeutic Applications in Cancer Medicine

Overview
Publisher Wiley
Date 2021 May 17
PMID 33998154
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

It has been almost two decades since the first link between microRNAs and cancer was established. In the ensuing years, this abundant class of short noncoding regulatory RNAs has been studied in virtually all cancer types. This tremendously large body of research has generated innovative technological advances for detection of microRNAs in tissue and bodily fluids, identified the diagnostic, prognostic, and/or predictive value of individual microRNAs or microRNA signatures as potential biomarkers for patient management, shed light on regulatory mechanisms of RNA-RNA interactions that modulate gene expression, uncovered cell-autonomous and cell-to-cell communication roles of specific microRNAs, and developed a battery of viral and nonviral delivery approaches for therapeutic intervention. Despite these intense and prolific research efforts in preclinical and clinical settings, there are a limited number of microRNA-based applications that have been incorporated into clinical practice. We review recent literature and ongoing clinical trials that highlight most promising approaches and standing challenges to translate these findings into viable microRNA-based clinical tools for cancer medicine. This article is categorized under: RNA in Disease and Development > RNA in Disease.

Citing Articles

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.


Migraine and stroke: correlation, coexistence, dependence - a modern perspective.

Boronczyk M, Zdunska A, Wegrzynek-Gallina J, Grodzka O, Lasek-Bal A, Domitrz I J Headache Pain. 2025; 26(1):39.

PMID: 39979846 PMC: 11844069. DOI: 10.1186/s10194-025-01973-w.


A Systematic Review of Circulating miRNAs Validated by Multiple Independent Studies in Laryngeal Cancer.

Banta A, Bratosin F, Golu I, Toma A, Domuta E Diagnostics (Basel). 2025; 15(3).

PMID: 39941323 PMC: 11817663. DOI: 10.3390/diagnostics15030394.


Salivary miRNAs and cytokines associated with diagnosis and prognosis of oral squamous cell carcinoma.

Qin Y, Dong X, Li B Front Cell Dev Biol. 2025; 13:1531016.

PMID: 39911325 PMC: 11794800. DOI: 10.3389/fcell.2025.1531016.


Integrative analysis of miRNA expression data reveals a minimal signature for tumour cells classification.

Napoletano S, Dannhauser D, Netti P, Causa F Comput Struct Biotechnol J. 2025; 27:233-242.

PMID: 39866665 PMC: 11760817. DOI: 10.1016/j.csbj.2024.12.023.


References
1.
Gokita K, Inoue J, Ishihara H, Kojima K, Inazawa J . Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy. Mol Ther Nucleic Acids. 2019; 19:330-338. PMC: 6938807. DOI: 10.1016/j.omtn.2019.10.045. View

2.
Schwarzenbach H . Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients. Oncol Res Treat. 2017; 40(7-8):423-429. DOI: 10.1159/000478019. View

3.
Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

4.
Zheng R, Mao W, Du Z, Zhang J, Wang M, Hu M . Three differential expression profiles of miRNAs as potential biomarkers for lung adenocarcinoma. Biochem Biophys Res Commun. 2018; 507(1-4):377-382. DOI: 10.1016/j.bbrc.2018.11.046. View

5.
Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald S . Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2013; 83(2):272-8. DOI: 10.1016/j.lungcan.2013.11.005. View